key: cord-0032063-ttf69i7o
authors: Zou, Henry; Daveluy, Steven
title: Pemphigus Vulgaris after COVID-19 Infection and Vaccination
date: 2022-05-13
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2022.05.013
sha: f7c74712e4c720d724d69214e546347f8e62b00d
doc_id: 32063
cord_uid: ttf69i7o

nan

PV has been reported very rarely following COVID-19 infection and vaccination. The benefits of COVID-19 vaccines significantly outweigh the risks, particularly for the PV patient population due to their heightened risk for COVID-19 infection and severe complications such as long-term health impairments and death. 5 We recommend that healthcare providers discuss the risks and benefits of receiving the COVID-19 vaccine with sensitivity and transparency and remain vigilant against the rare but severe risk of post-vaccine PV onset.

J o u r n a l P r e -p r o o f

Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity

Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine

Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2

Oral pemphigus after COVID-19 vaccination

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence